Table 3.

ORs and 95% CIs comparing HPV seropositivity in adenoma and hyperplastic cases to controls, stratified by sex, participants without previous polyps: Group Health members, 1998–2003

 Women (N = 184)
Controls (n = 118)Adenomas (n = 39)Hyperplastic polyps (n = 27)
Pos, n (%)Pos, n (%)Crude ORAdjusteda ORPos, n (%)Crude ORAdjusteda OR
Any type53 (45)14 (36)0.69 (0.33–1.45)0.79 (0.35–1.75)10 (37)0.72 (0.30–1.71)0.87 (0.34–1.75)
HPV-1631 (26)6 (15)0.51 (0.19–1.33)0.60 (0.22–1.64)5 (19)0.64 (0.22–1.83)0.81 (0.25–2.54)
HPV-1813 (11)4 (10)0.92 (0.28–3.01)1.22 (0.34–4.28)0 (0)0 (0–1.17)N/Ab
HPV-16 or -1835 (30)9 (23)0.71 (0.31–1.65)0.86 (0.35–2.11)5 (19)0.54 (0.19–1.54)0.65 (0.21–2.06)
HPV-3114 (12)3 (8)0.74 (0.19–2.84)0.70 (0.18–2.69)3 (11)0.93 (0.25–3.49)1.84 (0.44–7.72)
HPV-3313 (11)2 (5)0.44 (0.09–2.03)0.38 (0.08–1.82)2 (7)0.65 (0.14–3.05)0.41 (0.07–2.20)
HPV-356 (5)2 (5)1.00 (0.20–5.21)1.16 (0.21–6.37)2 (7)1.49 (0.28–7.84)2.28 (0.37–14.02)
HPV-395 (4)1 (3)0.59 (0.07–5.25)0.70 (0.08–6.60)1 (4)0.87 (0.10–7.76)1.84 (0.18–18.77)
HPV-453 (3)1 (3)1.01 (0.10–9.99)0.92 (0.09–9.60)0 (0)0 (0–5.87)N/Ab
HPV-527 (6)1 (3)0.42 (0.05–3.50)0.41 (0.05–3.45)1 (4)0.61 (0.07–5.18)0.75 (0.08–6.80)
HPV-588 (7)1 (3)0.36 (0.04–2.98)0.38 (0.04–3.34)0 (0)0 (0–2.13)N/Ab
HPV-681 (1)0 (0)0 (0–5.72)N/Ab0 (0)0 (0–9.29)N/Ab
 Men (N = 124)
Controls (n = 68)Adenomas (n = 32)Hyperplastic polyps (n = 24)
Pos, n (%)Pos, n (%)Crude ORAdjustedaORPos, n (%)Crude ORAdjustedaOR
Any type17 (25)12 (38)1.80 (0.73–4.44)1.74 (0.65–4.64)12 (50)3.00 (1.14–7.91)3.10 (1.04–9.29)
HPV-168 (12)5 (16)1.39 (0.42–4.64)1.33 (0.37–4.76)5 (21)1.97 (0.58–6.76)2.42 (0.62–9.44)
HPV-182 (3)2 (6)2.20 (0.30–16.37)1.84 (0.23–14.87)4 (17)6.60 (1.12–38.73)5.72 (0.84–38.71)
HPV-16 or -189 (13)7 (22)1.84 (0.62–5.48)1.88 (0.59–5.97)6 (25)2.19 (0.69–6.97)2.70 (0.75–9.65)
HPV-315 (7)4 (13)1.80 (0.45–7.21)1.71 (0.39–7.42)4 (17)2.52 (0.62–10.30)2.12 (0.46–9.70)
HPV-332 (3)4 (13)4.71 (0.82–27.24)4.54 (0.75–27.66)6 (25)11.00 (2.04–59.20)13.71 (2.28–82.29)
HPV-351 (1)0 (0)0 (0–4.18)N/Ab4 (17)13.39 (1.42–126.68)10.21 (0.76–137.82)
HPV-390 (0)1 (3)∞ (0.03–∞)N/Ac1 (4)∞ (0.04–∞)N/Ac
HPV-450 (0)2 (6)∞ (1.13–∞)N/Ac1 (4)∞ (0.04–∞)N/Ac
HPV-524 (6)2 (6)1.07 (0.19–6.15)1.02 (0.16–6.41)3 (13)2.29 (0.47–11.05)2.08 (0.35–12.31)
HPV-580 (0)1 (3)∞ (0.03–∞)N/Ac0 (0)N/AdN/Ad
HPV-680 (0)0 (0)N/AdN/Ad0 (0)N/AdN/Ad
  • aAdjusted for age, race, smoking status, BMI, alcohol consumption, and education.

  • bZero cases seropositive, only crude OR (95% CI) can be calculated.

  • cZero controls seropositive, only crude OR (95% CI) can be calculated.

  • dZero cases and 0 controls seropositive.